Ovid Therapeutics Inc
OVID
查看详细走势图
2.110USD
-0.190-8.26%
收盘 03/30, 16:00（美东）报价延迟15分钟
51.91M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-8.26%
5天
-17.25%
1月
+27.11%
6月
+62.31%
今年开始到现在
+29.45%
1年
+502.86%
查看详细走势图
TradingKey Ovid Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Ovid Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名82/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.80。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Ovid Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Ovid Therapeutics Inc亮点
亮点风险
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
业绩高增长
公司营业收入稳步增长，连续3年增长1751.44%
业绩增长期
公司处于发展阶段，最新年度总收入7.25M美元
估值低估
公司最新PE估值-9.74，处于3年历史低位
机构减仓
最新机构持股43.75M股，环比减少5.23%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值3.07M
活跃度降低
近期活跃度降低，过去20天平均换手率1.92
分析师目标
根据
11
位分析师
买入
评级
4.711
目标均价
+91.51%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Ovid Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Ovid Therapeutics Inc简介
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
公司代码OVID
公司Ovid Therapeutics Inc
CEOAlexander (Margaret A)
网址https://ovidrx.com/
相关品种
